RejuvenAir Lobectomy for Safety and Histology (LobectomyCAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02483052
Recruitment Status : Completed
First Posted : June 26, 2015
Last Update Posted : May 11, 2017
Information provided by (Responsible Party):
CSA Medical, Inc.

Brief Summary:
RejuvenAir System treatment will be performed during preoperative bronchoscopy 2 to 90 days prior to prescheduled lung resection in Subjects requiring lobectomy for removal of peripheral tumors. Treatment will be limited to areas of the bronchi within the lobe that will be removed, distal to the anticipated margin of resection. Treatment should be at least 1 cm from the bronchial resection margins and away from the tumor bed. Treated airways will be inspected via bronchoscopy at the time of thoracotomy, and examined histologically following surgical resection. Subject participation will be from 1 to 90 days and enrollment is anticipated to take 3 months. Subject having a RejuvenAir procedure and not going on to a resection for any reason will be followed for a maximum of 90 days for safety and undergo bronchoscopic evaluation of the treated airways at 90 days (+/- 4 Days)) post treatment.

Condition or disease Intervention/treatment Phase
Lung Neoplasms Pulmonary Neoplasms Device: RejuvenAir Phase 1 Phase 2

Detailed Description:
The study is a prospective, open label, single arm, single center study. The objective is to study the safety of the RejuvenAir System in a population of subjects who are scheduled to undergo a planned lobectomy. A secondary objective is to determine the histological effects of RejuvenAir System treatment in the airways. The Primary Endpoint is Safety as measured by occurrence of serious adverse events related to metered dose radial spray cryotherapy treatment performed prior to scheduled lobectomy surgery. The patient population intended to participate in this study are subjects scheduled to undergo lobectomy for peripheral lung lesions suspicious for or known to be cancer. Secondarily, this will enable an understanding of the histological characteristics and healing outcomes post-treatment in the airways, which will be resected. CSA Medical has conducted bench and animal studies that support the use of the RejuvenAir System as sufficiently safe and effective to warrant advancing the product into this primary safety study in patients presenting for consideration of lobectomy. Such patients provide a safe population to further the clinical evaluation of the system in that these subjects will receive their lobectomy or procedure 2 to 14 days following delivery of their metered liquid nitrogen treatment. At the time of their metered liquid nitrogen treatment they will be in an operating room setting with their thoracic surgeon in attendance. It is anticipated that subjects who agree to participate in this study will have the metered liquid nitrogen treatment at the time of evaluation of their lung lesion. This evaluation will include bronchoscopy with ultrasound for evaluation of their lymph nodes prior to the planned surgical resection of their lung abnormality.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Intervention Model Description: RejuvenAir
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Prospective Study of RejuvenAir System Radial Spray Cryotherapy to Determine Safety and Delayed Histological Effect in the Lung
Study Start Date : August 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: RejuvenAir
RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
Device: RejuvenAir
Other Name: RejuvenAir™ System Radial Spray Cryotherapy

Primary Outcome Measures :
  1. Safety measured by occurrence of serious adverse events related to metered dose radial spray cryothreapy [ Time Frame: prior to lobectomy-up to 14 days ]

Secondary Outcome Measures :
  1. Histology assessed by description of depth of histological treatment effect per specified treatment dose [ Time Frame: up to 90 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females of 21 to 75 years of age.

    • Subject is able to read, understand, and sign a written Informed Consent to participate in the study.
    • Subject is scheduled within 90 days from date of study treatment for a lobectomy unrelated to this study (upper and lower lobes only). Preferred range is 2-14 days from study treatment.
    • Subject has a pre-procedure post bronchodilator FEV1 of greater than or equal to 40% of predicted.
    • Subject is able to undergo bronchoscopy in the opinion of the investigator or per hospital guidelines.
    • Subject is able to adhere to and undergo a scheduled bronchoscope procedure prior to their clinically scheduled lobectomy surgical procedure.

Exclusion Criteria:

  • • Subject is pregnant, nursing, or planning to get pregnant during study duration.

    • Subject is scheduled to have a pneumonectomy or has had a previous contralateral pneumonectomy.
    • Subject has had prior radiation therapy which involved the lungs.
    • Subject has received chemotherapy within the past 6 months, or is anticipated to be treated with chemotherapy between initial study treatment and lobectomy procedure.
    • Subject has an acute pulmonary infection or pneumonia within 6 weeks prior to study bronchoscopy.
    • Subject has had COPD exacerbation within 6 weeks prior to study bronchoscopy.
    • Subject has bronchiectasis in the area to be treated.
    • Subject has bullous emphysema. Characterized as large bullae >3 centimeters and confirmed on CT.
    • Subject has had a Lung transplant.
    • Subject has had lung reduction surgery, including implanted emphysema stent (s) implanted, coils or other devices for treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02483052

Canada, Ontario
William Osler Health System
Brampton, Ontario, Canada, L6R 3J7
Sponsors and Collaborators
CSA Medical, Inc.
Principal Investigator: Kashif Irshad, MDCM, MSc WIlliam Osler Health Systems

Responsible Party: CSA Medical, Inc. Identifier: NCT02483052     History of Changes
Other Study ID Numbers: 013
First Posted: June 26, 2015    Key Record Dates
Last Update Posted: May 11, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by CSA Medical, Inc.:
spray cryotherapy
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases